In this interview, Hanna Ritzén (Mercodia; Uppsala, Sweden) provides an insight into her recent article on classification of commercial LBA kits for biomarkers, and why this area of bioanalysis is important.
Browsing: Spotlight Resources
John Chappell (Gyros Protein Technologies; Uppsala Sweden) discusses features of Gyrolab technology that make it a must-have in biotherapeutics development and manufacturing.
As part of our Spotlight on flow cytometry, we carried out a survey to gain an insight into the trends, challenges and developments associated with this technique – find out the results in this informative infographic.
Developed by over 40 international experts, this set of practical guidelines is useful to in vitro diagnostic (IVD) innovators, clinical laboratories, regulatory scientists, and laboratory inspectors.
Tanja Jarhede, Senior Scientist, Mercodia AB, (Uppsala, Sweden) 1. Could you introduce yourself and explain…
Product: Gyrolab® xPand – the automated, high- throughput immunoassay system that maximizes productivity in biotherapeutic discovery, development and production
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassay platforms and leading provider of peptide synthesizers and reagents has developed Gyrolab® xPand to provide high-throughput, flexibility and rapid analysis of large sample numbers for a range of biotherapeutic applications. The proprietary Gyrolab CD technology, with highly reproducible nanoliter microfluidics, is integrated with Gyrolab platforms to automate nanoliter-scale immunoassays with parallel processing, using laser-induced fluorescence detection.
Evaluation of therapeutic antibody performance with multiple nanolitre-scale immunoassays in a single run
Find out more about the evaluation of therapeutic antibody performance with multiple nanolitre-scale immunoassays in a single run in this poster from Gyros Protein Technologies.
Authors Frida Henningson Johnson, Hampus Elofsson, Esrat Qamrul-Ehsan and Hanna Ritzén, Mercodia AB (Uppsala, Sweden)…
In these three posters, Charles Rivers (MA, USA) discuss the challenges associated with flow cytometry validation, compare data generated against that by microscopy, and compile historical immunophenotyping data in preclinical species.
In this manuscript, the European Bioanalysis Forum presents additional practice guidance on the use of flow cytometry in the support of drug development programs and addresses areas that are not covered in the previous publications.